GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SpA (NYSE:STVN) » Definitions » 5-Year Share Buyback Ratio

STVN (Stevanato Group SpA) 5-Year Share Buyback Ratio : 2.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SpA 5-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Stevanato Group SpA's current 5-Year Share Buyback Ratio was 2.00%.

STVN's 5-Year Share Buyback Ratio is ranked better than
97.6% of 668 companies
in the Medical Devices & Instruments industry
Industry Median: -4.55 vs STVN: 2.00

Competitive Comparison of Stevanato Group SpA's 5-Year Share Buyback Ratio

For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stevanato Group SpA's 5-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's 5-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Stevanato Group SpA's 5-Year Share Buyback Ratio falls into.


;
;

Stevanato Group SpA 5-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Stevanato Group SpA (NYSE:STVN) 5-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Stevanato Group SpA 5-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Stevanato Group SpA's 5-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Stevanato Group SpA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SpA (NYSE:STVN) » Definitions » 5-Year Share Buyback Ratio
Comparable Companies
MMSI TFX RGEN ICUI XRAY NVST WRBY LMAT AZTA ATRC ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XSWX:STMN XPAR:DIM
Traded in Other Exchanges
87N:Germany
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Website
https://www.stevanatogroup.com
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.